Denmark's Bavarian Nordic said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its mpox and smallpox vaccine.

An advisory panel on vaccines meets, carefully, in the shadow of a health secretary who has often criticized it.

The FDA has approved a new freeze-dried formulation of Jynneos (smallpox and mpox vaccine, live, non-replicating).

A recent study carried out at Charité Universitätsmedizin Berlin and published in The Lancet Infectious Diseases has shown that one dose of Bavarian Nordic’s Jynneos (smallpox and mpox vaccine ...

Health officials are advising people at higher risk of mpox infection to consider being vaccinated with two doses of the JYNNEOS vaccine, which is available statewide. Laboratory testing of the ...

The state will receive 5,943 doses of the Jynneos vaccine from the Strategic National Stockpile during the first two phases, Dr. Alexander Millman, chief medical officer for the Georgia Department ...

Bavarian Nordic said it was contracted by the U.S Biomedical Advanced Research and Development Authority to develop and supply the freeze-dried version of Jynneos for stockpiling.

COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS ...

Marketed as Jynneos in the US, the vaccine currently exists in a liquid-frozen formulation. These products require a temperature-controlled supply chain that keeps them frozen between production ...

COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS ® (Smallpox ...